Puma Biotechnology, Inc. (PBYI)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awa.

Puma Biotechnology, Inc. ( PBYI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber Roger Storms Maximo F. Nougues - CFO & Principal Accounting Officer Conference Call Participants Marc Frahm - TD Cowen, Research Division Presentation Operator Good afternoon.

Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.

Puma Biotech (PBYI) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.45 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.

Ethic Inc. acquired a new position in Puma Biotechnology, Inc. (NASDAQ: PBYI) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 15,168 shares of the biopharmaceutical company's stock, valued at approximately $51,000. Other institutional investors have also recently

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.

There's a small portion of my portfolio I allocate toward companies I'd put in the “higher risk” bucket.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of one inducement award to a new hire in Sept. 2025, as required by Nasdaq Listing Rule 5635(c)(4).

Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.